Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.44 |
| ▸ | TUBB | P07437 | 5/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12937497 | 0.82 | CYP3A4 (0.52) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL686849 | 0.79 | CYP1A2 (0.64) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL17181762 | 0.79 | ABL1 (0.47) | CYP3A4MAPTCA9PTGS2CYP1A2 | |
| SCHEMBL11448 | 0.76 | ALDH1A1 (0.36) | ACHECYP3A4MAPTCA9ALDH1A1 | |
| SCHEMBL6732214 | 0.74 | ALDH1A1 (0.40) | PTGS2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL23115 | 0.74 | CA2 (0.67) | ACHECYP3A4MAPTCA9CYP1A2 | |
| SCHEMBL4641984 | 0.74 | TUBB1 (0.37) | CYP3A4CA9CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL5877432 | 0.74 | ALDH1A1 (0.65) | CYP3A4CA9PTGS2CYP1A2CYP1A1 | |
| SCHEMBL2092814 | 0.73 | ACHE (0.54) | ACHECYP3A4MAPTCA9PTGS2 | |
| Formaldehyde SCHEMBL28179692 | 0.73 | CYP1A2 (0.57) | ACHECYP3A4MAPTCA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| US-9611281-B2 | BODIPY derivatives and methods of synthesis and use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351911-A2 | MATERIALS AND METHODS FOR SYNTHESIZING STILBENES | Cancer Research Ventures Limited (GB) | 2003-10-15 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002049994-A2 | MATERIALS AND METHODS FOR SYNTHESIZING STILBENES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | ACHE 809/4885CYP3A4 124/4885MAPT 4376/4885 |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | ACHE 3522/4885CYP3A4 4064/4885MAPT 2614/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | ACHE 3522/4885CYP3A4 4064/4885MAPT 2614/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | ACHE 3522/4885CYP3A4 4064/4885MAPT 2614/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | ACHE 2287/4885CYP3A4 4315/4885MAPT 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.